These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors. Abbrescia VD; Pearlstein L; Kotler M J Am Osteopath Assoc; 1997 Mar; 97(3):162-4. PubMed ID: 9107127 [TBL] [Abstract][Full Text] [Related]
25. Building on the sumatriptan experience: the development of naratriptan. Connor HE Cephalalgia; 2001; 21 Suppl 1():32-4. PubMed ID: 11678820 [No Abstract] [Full Text] [Related]
26. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776 [TBL] [Abstract][Full Text] [Related]
27. A surfeit of serotonin: sumatriptan and serotonergic antidepressants. Schwartz CE Arch Intern Med; 1999 May; 159(10):1141-2. PubMed ID: 10335694 [No Abstract] [Full Text] [Related]
28. Vasospasm induced myocardial ischaemia secondary to sumatriptan use. Okonkwo K; Ojha U BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32843411 [TBL] [Abstract][Full Text] [Related]
29. Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew. Goldstein D Cephalalgia; 1999 Jun; 19(5):536-7. PubMed ID: 10403072 [No Abstract] [Full Text] [Related]
30. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. O'Quinn S; Davis RL; Gutterman DL; Pait GD; Fox AW Cephalalgia; 1999 May; 19(4):223-31; discussion 200. PubMed ID: 10376167 [TBL] [Abstract][Full Text] [Related]
32. [Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients]. Géraud G; Valette C Rev Neurol (Paris); 2000 Jul; 156(6-7):646-53. PubMed ID: 10891800 [TBL] [Abstract][Full Text] [Related]
33. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Visser WH; Jaspers NM; de Vriend RH; Ferrari MD Cephalalgia; 1996 Dec; 16(8):554-9. PubMed ID: 8980858 [TBL] [Abstract][Full Text] [Related]
34. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Göbel H; Heinze A; Stolze H; Heinze-Kuhn K; Lindner V Cephalalgia; 1999 Sep; 19(7):676-83; discussion 626. PubMed ID: 10524662 [TBL] [Abstract][Full Text] [Related]
35. Coronary side-effect potential of current and prospective antimigraine drugs. MaassenVanDenBrink A; Reekers M; Bax WA; Ferrari MD; Saxena PR Circulation; 1998 Jul; 98(1):25-30. PubMed ID: 9665056 [TBL] [Abstract][Full Text] [Related]
36. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case. Stillman MJ; Tepper S; Tepper DE; Cho L Headache; 2013 Jan; 53(1):208-216. PubMed ID: 23216317 [TBL] [Abstract][Full Text] [Related]
37. How to assess patient preference of migraine treatments. Dahlöf C Cephalalgia; 1999 Jul; 19 Suppl 24():2-5; discussion 5-6. PubMed ID: 10526675 [No Abstract] [Full Text] [Related]
38. Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. Foster JM; Houghton LA; Whorwell PJ; Morris J Aliment Pharmacol Ther; 1999 Jul; 13(7):927-36. PubMed ID: 10383528 [TBL] [Abstract][Full Text] [Related]
39. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Deleu D; Hanssens Y Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351 [TBL] [Abstract][Full Text] [Related]
40. Transient global amnesia, migraine, thalamic infarct, dihydroergotamine, and sumatriptan. Pradalier A; Lutz G; Vincent D Headache; 2000 Apr; 40(4):324-7. PubMed ID: 10759939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]